Pierre Fabre's vinflunine receives an EU positive opinion in bladder cancer
This article was originally published in Scrip
Executive Summary
Pierre Fabre's new vinca alkaloid anticancer, Javlor (vinflunine ditartrate, 25mg/ml), has received a positive opinion from the EU's CHMP, for the second-line treatment of transitional cell carcinoma of the urothelium.